About: Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.
Sector: Healthcare
Industry: Biotechnology
Latest price: $152.48 (-0.46%)
PVLA NASDAQ Palvella Therapeutics, Inc
Palvella Therapeutics, Inc share price
PVLA price activity
Last Price
$152.480
Change (24hr)
-0.70 USD (0.46%)
Volume
239.71K
Volume (4w avg)
-
Open
$153.00
Day Range
$149.81 - $156.71
Previous Close
$153.18
Last Trade
13 Nov, 9:00 pm GMT+0
Delayed
13 Nov, 9:00 pm GMT+0
PVLA price performance
Delayed
13 Nov, 9:00 pm GMT+0
PVLA details
PVLA Market Signals